Overview

Arimoclomol in Sporadic Inclusion Body Myositis

Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
Inclusion body myositis (IBM) is the most common progressive and debilitating muscle disease beginning in persons over 50 years of age. This study will assess the safety and tolerability of Arimoclomol in IBM as compared to placebo over 4 months of treatment.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Richard Barohn, MD